Xenon Pharmaceuticals Inc. (XENE)
Develops experimental drugs targeting brain cell channels to treat epilepsy and psychiatric disorders.
$64.94-0.01%Healthcare
StockGlow Score
Bullish
BearishBullish
1 year ago+112.9%
The outlook
Xenon Pharmaceuticals trades near the upper end of its 52-week range, with the stock positioned above both its 50- and 200-day moving averages. Analyst consensus leans strongly bullish across 19 firms, with an average price target about 25% above the current level. The overall sentiment skews notably positive based on current market positioning.
What’s behind the score
Analyst consensusStrong Buy — 1.1 avg of 19 analysts
Price trendAbove its 50- & 200-day averages
52-week range82% of the way from its 52-week low to high
Price targetAvg target +25% vs current price
Analyst price target
~12-month · 19 analysts$80.93average target+24.6% vs now
Now $64.94
Low $63.00High $100.00
Published targets from Wall Street analysts (public data) — what analysts expect over roughly a year. This is not a StockGlow forecast and not a recommendation. Analyst targets are frequently wrong.
Market cap
$6.28B
52-wk high
$72.66
52-wk low
$30.00
50-day avg
$58.46
200-day avg
$49.66
Trailing P/E
—